Browse every story filed under this topic, curated from trusted publishers around the world.
Axsome Drug’s FDA Approval Unlocks New Opportunity in Alzheimer’s Agitation
Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axsome’s pill has a safety advantage. The post Axsome Drug’s FDA Approval …
Read full story →
Legionnaires’ disease connected to 5-star Wynn resort in Las Vegas, officials say
Cases of the disease – which kills 1 of 10 who fall ill – have been rising since the early …
Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation
Four years after gaining FDA approval for Auvelity to treat major depressive disorder, Axsome Therapeutics has tacked on a second …
Syphilis making a comeback, health officials warn. CDC map shows where risk is highest
Compared to about a decade ago, the Centers for Disease Control and Prevention said congenital syphilis cases are 700% higher …
FDA approves new Alzheimer’s agitation treatment
The FDA has approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) to treat agitation associated with dementia …
Why Metabolic Health Is a Common Thread Across Diabetes, Heart Disease, and Some Cancer
A common mechanism for reversing metabolic disease in some patients seems to be the sustained flattening of the hills and …
How the UK quietly became a research powerhouse in the fight against malaria
The UK is driving pioneering malaria research in areas including genetic engineering, vaccines, and medicines. In Tanzania, the scientists involved …
This Common Workplace Habit Carries Risks Comparable to Smoking
Sitting for hours at a time has been linked to heart disease, diabetes, and early death, and even regular exercise …
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.
Merck bats for heart disease awareness with new baseball-inspired campaign
Merck is making its pitch that high levels of so-called “bad cholesterol” can increase the risk of heart attack or …
Eliminating MIS deserts: How Ballad Health expanded da Vinci surgery across rural Appalachia
Rural patients face a well-documented paradox in surgical care: they carry a higher burden of chronic disease and experience worse …
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition
KalVista Pharmaceuticals brings to Chiesi Group the product Ekterly, the first FDA-approved oral drug for acute treatment of swelling attacks …
Regeneron's quarterly sales of Eylea drop below $1B for the first time in 8 years
As regulatory delays continue to plague Regeneron's Eylea franchise, quarterly sales for the eye disease medicine have dropped below $1 …
Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
Meta-analysis backs broader use of BP therapy in CKD
A recent study highlighted that lowering blood pressure (BP) reduces major cardiovascular events in people with chronic kidney disease (CKD). …
Why Banner, Penn Medicine invest in research amid funding cuts
The math on American healthcare spending and research dollars are hard to swallow. Many academic health systems have seen funding …
Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout
As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare disease med …
Rocket to sell PRV for $180m to advance gene therapy pipeline
Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease PRV for $180m to advance its gene therapy …
Capturing Incarceration in the Medical Record: We Cannot Manage What We Cannot Measure
Abstract Nearly two million people are incarcerated in United States jails and prisons, where they experience disproportionate burdens of chronic …
Rocket sells priority review voucher for $180M after Kresladi gene therapy approval
Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher, striking a $180 million sale that reflects …
You've seen all articles for #disease.
Check back
soon
for new stories.